Considered as one of the greatest threats to mankind, infectious diseases are responsible for 15% of all deaths worldwide, and transmission rates remain high due to increasingly transient and concentrated global populations (source WHO). Through science and innovation, The Janssen Pharmaceutical Companies of Johnson & Johnson aims to deliver an end-to-end approach to prevent, treat and cure infectious diseases. It is our goal to ensure a future where we can hopefully prevent the spread of infectious diseases and eliminate the burden they place on global health, but we can’t do it alone.
On 28 January 2020, JLABS will be hosting a lively discussion featuring leaders in the field who can share the opportunities and challenges of medicines aiming to help fight infectious diseases. The event is hosted at the Naturalis Biodiversity Center in Leiden on 28 January, and will feature a lively discussion on the state of the art in the fight against infectious diseases worldwide and also in the Netherlands.
Moderator: Johan Van Hoof, Global Therapeutic Area Head of Infectious Diseases and Vaccines, Janssen Pharmaceutica
Marc Bonten, Head, Department of Medical Microbiology, UMC Utrecht
Coen Breedveld, Co-founder, Levels Diagnostics
Marion Koopmans, Head of the Viroscience, Department of the Erasmus MC Rotterdam
Peter Reiss, Professor of Medicine, UMC Amsterdam
Meta Roestenberg, Specialist, Department of Infectious Diseases, Leiden University Medical Center
HollandBIO is de belangenvereniging van biotech bedrijven in Nederland. Samen werken we aan ons toekomstideaal: een maatschappij waarin biotechnologie maximaal bijdraagt aan gezondheid, duurzaamheid en economische groei.
Laan van Nieuw Oost-Indië 131-133
2593 BM Den Haag
Laan van Nieuw Oost-Indië 131 E
2593 BM Den Haag